Categories: News

Cheelcare Turns Heads at the Canadian Seating and Mobility Conference in Toronto

Toronto, Ontario–(Newsfile Corp. – September 11, 2025) – Cheelcare Inc. (TSXV: CHER) (“Cheelcare” or the “Company”), a Canadian leader in assistive mobility devices, turned heads at the 2025 Canadian Seating and Mobility Conference (CSMC), one of Canada’s premier gatherings for rehabilitation professionals, clinicians, and mobility industry leaders.

Providers try Curio at Cheelcare’s booth at the 2025 CSMC

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11847/265899_csmc1.jpg

Cheelcare presented its latest updates to the Companion power-assist system alongside the company’s newest innovation, Curio – Cheelcare’s complex rehab power wheelchair built on their patented robotic platform. Both devices are designed to provide wheelchair users with enhanced quality of life and independence.

Cheelcare’s Sales Representative for Ontario Demonstrates Newest Companion Product Updates at 2025 CSMC

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11847/265899_csmc2.jpg

“CSMC is Canada’s largest event for our industry and allows us to directly connect with the clinicians, providers, and assistive technology professionals who are on the front lines of mobility care,” said Allan Boyd, Cheelcare’s VP of Growth. “The response to both Companion and Curio has been very positive and highlights the demand for more innovative solutions in the mobility market.”

About Cheelcare Inc.
Cheelcare designs and manufactures innovative mobility solutions that empower independence for people with disabilities. From the Companion power assist devices to the groundbreaking Curio robotic wheelchair, Cheelcare combines engineering excellence with human-centered design to improve quality of life.

For more information, please visit: www.cheelcare.ca.

For further information, please contact:
Allex Laurin, Director of Marketing
Cheelcare Inc.
Tel: 1-888-948-2680 x200
Email: alaurin@cheelcare.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265899

Staff

Recent Posts

Lightera Advances Fiber-integrated Temperature Feedback for Safer Laser-based Medical Procedures

SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- BiOS - Hall D Booth #8430, Photonics West Hall…

2 hours ago

DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

7 hours ago

NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…

8 hours ago

University of Phoenix and LinkedIn to host webinar on AI in nursing with skills and strategies for a new era of healthcare

January 22 virtual event "AI in Action: Skills and Strategies for a New Era of…

8 hours ago

Instinct Science Acquires ScribbleVet to Deliver the Next Generation of Intelligent-Native Veterinary Practice Management Software

The combination redefines PIMS by embedding AI, workflow, and clinical intelligence into a single system…

8 hours ago

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

13 hours ago